Table 2.
Results for CUBN SNP rs1801239 on chromosome 10 in the CKDGen and CARe Consortiaa and DCCT/EDIC
| UACR P Valueb | Microalbuminuria P valuec | Odds Ratio (95% CI) for Clinical Outcomes per Copy of Minor C Allele | |
|---|---|---|---|
| Overall samples | Microalbuminuria (MA) | ||
| CKDGen Stage 1 discovery | 3.0 × 10−7 | 8.7 × 10−7 | 1.25 (1.15 to 1.37) |
| CARe IBC discovery in European Americans | 2.9 × 10−10 | 2.4 × 10−7 | 1.31 (1.18 to 1.45) |
| CKDGen Stage 2 follow-up | 0.02 | 0.43 | 1.01 (0.98 to 1.05) |
| Combined populations of European ancestryd | 1.1 × 10−11 | 0.001 | 1.06 (1.02 to 1.09) |
| CARe African Americans | 0.005 | 0.008 | 1.42 (1.10 to 1.84) |
| Diabetes stratifiedd | |||
| no diabetes | 3.2 × 10−8 | 0.06 | 1.03 (1.00 to 1.07) |
| diabetes | 0.006 | 4.7 × 10−4 | 1.27 (1.11 to 1.45) |
| Hypertension stratifiede | |||
| no hypertension | 1.3 × 10−6 | 6.0 × 10−4 | 1.23 (1.09 to 1.38) |
| hypertension | 7.5 × 10−8 | 1.4 × 10−7 | 1.34 (1.20 to 1.49) |
| DCCT/EDICf | |||
| Persistent MA | |||
| simple model | 0.02 | 1.42 (1.08 to 1.88) | |
| extended model | 0.02 | 1.41 (1.06 to 1.87) | |
| Severe Nephropathy | |||
| simple model | 0.53 | 1.14 (0.76 to 1.69) | |
| extended model | 0.67 | 1.10 (0.72 to 1.67) |
aSample sizes are as follows (microalbuminuria case numbers in parentheses): CKDGen Stage 1: 31580 (3698); CARe European Americans: 19,499 (2100); CKDGen Stage 2: 27,746 (3313); CARe African Americans: 6981 (1159).
bP values from CKDGen and CARe European and African American Stage 1 analyses are from the inverse variance weighted fixed effects method, and P values from the CKDGen Stage 2 analyses, the combined analyses, and the hypertension- and diabetes-stratified analyses are from the sample size weighted Z score method. In all analyses, the minor allele C showed an increase in UACR, direction consistent with the odds ratio for MA.
cP values from inverse variance weighted fixed effects model.
dCombined populations of European ancestry, includes CKDGen Stages 1 and 2 (after removal of ARIC, CHS, and FHS) and all five cohorts of CARe European Americans: 63,153 (7383 microalbuminuria cases).
eCombined populations of European ancestry, includes CKDGen Stage 1 (after removal of ARIC, CHS, and FHS) and all five cohorts of CARe European Americans: 36,166 (4128 microalbuminuria cases).
fModeled as hazard ratio; n = 1304 including 318 cases of persistent microalbuminuria and 116 cases of severe nephropathy.